{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:15:56Z","timestamp":1792646156954,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2800,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>This study was undertaken to present data from a phase 2 study in which patients with unresectable hepatocellular carcinoma (HCC) with and without portal vein thrombosis underwent radioembolization with Yttrium (90Y) microspheres. Patients treated were stratified by Okuda, Child-Pugh, baseline bilirubin, tumor burden, Eastern Cooperative Oncology Group (ECOG), presence of cirrhosis and portal vein thrombosis (PVT) (none, branch, and main). Clinical and biochemical data were obtained at baseline and at 4-week intervals following treatment for up to 6 months. Tumor response was obtained using computed tomography (CT). Patients were followed for survival. One hundred eight patients were treated during the study period. Thirty-seven (34%) patients had PVT, 12 (32%) of which involved the main PV. The cumulative dose for those with and without PVT was 139.7 Gy and 131.9 Gy, respectively. The partial response rate using world Health Organization (WHO) criteria was 42.2%. Using European Association for the Study of the Liver (EASL), the response rate was 70%. Kaplan-Meier survival varied depending on location of PVT and presence of cirrhosis. The adverse event (AE) rates were highest in patients with main PVT and cirrhosis. There were no cases of radiation pneumonitis.<\/jats:bold>\n                      <jats:bold>Conclusion:<\/jats:bold>\n                      <jats:bold>The use of minimally embolic 90Y glass microspheres to treat patients with HCC complicated by branch\/lobar PVT may be clinically indicated and appears to have a favorable toxicity profile. Further investigation is warranted in patients with main PVT. (Hepatology 2007.)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.21980","type":"journal-article","created":{"date-parts":[[2007,11,20]],"date-time":"2007-11-20T19:16:28Z","timestamp":1195586188000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":505,"title":["Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis"],"prefix":"10.1097","volume":"47","author":[{"given":"Laura M.","family":"Kulik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Atassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent T.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert A.","family":"Nemcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa L.","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed A.","family":"Omary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20241201","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0016-5085(85)90327-0","article-title":"Incidence of portal vein thrombosis in liver cirrhosis: an angiographic study in 708 patients.","volume":"89","author":"Okuda","year":"1985","journal-title":"Gastroenterology"},{"key":"R2-13-20241201","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/00007890-199404270-00006","article-title":"Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation.","volume":"57","author":"Davidson","year":"1994","journal-title":"Transplantation"},{"key":"R3-13-20241201","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3748\/wjg.v7.i1.28","article-title":"Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.","volume":"7","author":"Fan","year":"2001","journal-title":"World J Gastroenterol"},{"key":"R4-13-20241201","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1440-1746.2001.02496.x","article-title":"Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement.","volume":"16","author":"Tazawa","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R5-13-20241201","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R6-13-20241201","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1051-0443(93)71873-4","article-title":"Hepatic chemoembolization: safety with portal vein thrombosis.","volume":"4","author":"Pentecost","year":"1993","journal-title":"J Vasc Interv Radiol"},{"key":"R7-13-20241201","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S1051-0443(07)61789-8","article-title":"Chemoembolization of hepatocellular carcinoma.","volume":"13","author":"Ramsey","year":"2002","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl 1","key":"R9-13-20241201","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1002\/lt.20036","article-title":"Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.","volume":"10","author":"Carr","year":"2004","journal-title":"Liver Transpl"},{"issue":"Suppl 1","key":"R10-13-20241201","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1053\/j.gastro.2004.09.034","article-title":"Yttrium90 microspheres for the treatment of hepatocellular carcinoma.","volume":"127","author":"Geschwind","year":"2004","journal-title":"Gastroenterology"},{"key":"R11-13-20241201","first-page":"49","article-title":"Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: transcatheter arterial chemoembolization versus yttrium90 glass microspheres.","volume":"3","author":"Goin","year":"2004","journal-title":"World J Nucl Med"},{"key":"R12-13-20241201","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00270-005-0171-4","article-title":"Treatment of unresectable primary and metastatic liver cancer with yttrium90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization.","volume":"29","author":"Sato","year":"2006","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R13-13-20241201","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.RVI.0000123319.20705.92","article-title":"Use of Yttrium90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.","volume":"15","author":"Salem","year":"2004","journal-title":"J Vasc Interv Radiol"},{"key":"R14-13-20241201","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma: conclusions of the Barcelona2000 EASL conference. European Association for the Study of the Liver.","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"R15-13-20241201","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria.","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"issue":"Suppl","key":"R17-13-20241201","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/S1051-0443(07)61790-4","article-title":"Yttrium90 microspheres: radiation therapy for unresectable liver cancer.","volume":"13","author":"Salem","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"R18-13-20241201","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","article-title":"Radioembolization with 90Yttrium microspheres: a stateoftheart brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations.","volume":"17","author":"Salem","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"R19-13-20241201","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0360-3016(95)00039-3","article-title":"Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttriummicrospheres for inoperable hepatic tumors.","volume":"33","author":"Leung","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-13-20241201","first-page":"1256","article-title":"Groupe dEtude et de Traitement du Carcinome Hepatocellulaire.","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"R21-13-20241201","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cncr.10694","article-title":"Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.","volume":"5","author":"Ando","year":"2002","journal-title":"Cancer"},{"key":"R22-13-20241201","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1148\/radiographics.19.2.g99mr08399","article-title":"Chemoembolization of hepatic neoplasms: safety, complications, and when to worry.","volume":"19","author":"Gates","year":"1999","journal-title":"Radiographics"},{"key":"R23-13-20241201","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.","volume":"35","author":"Lo","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R24-13-20241201","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M","article-title":"The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study.","volume":"79","author":"Lee","year":"1997","journal-title":"Cancer"},{"key":"R25-13-20241201","first-page":"79","article-title":"Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients.","volume":"49","author":"Carr","year":"2002","journal-title":"Hepatogastroenterology"},{"issue":"Suppl 1","key":"R26-13-20241201","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/lt.20034","article-title":"The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.","volume":"10","author":"Llovet","year":"2004","journal-title":"Liver Transpl"},{"key":"R27-13-20241201","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients.","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer"},{"key":"R28-13-20241201","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.","volume":"37","author":"Llovet","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R29-13-20241201","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.","volume":"29","author":"Llovet","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R30-13-20241201","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma.","volume":"42","author":"Bruix","year":"2005","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21980","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01515467-200801000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:53:41Z","timestamp":1786035221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01515467-200801000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21980","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}